Check out our wide range of resources, including articles, protocols, webinars, videos, posters and documentation.
  • Immuno-Oncology 2021
    Bethyl | Fortis presented at the Immuno-Oncology virtual event on the expanding need for validated antibodies.
  • Antibodies, The key to spatial mass spectrometry success
    In this webinar, join Dr. Mike Spencer, senior director of antibody validation and IHC at Fortis Life Sciences, as he explores effective strategies to ensure optimal antibody performance in multiplex IHC assays.
  • Direct ELISA Protocol
    This protocol outlines the procedure for performing direct ELISA methodology. Infomration includes required reagents, preparation of reagents and the procedure for all steps involved.
  • Preparation of Cell Lysate used for Immunoprecipitation
    See the protocol outlining the preparation of cell lysate used in immunoprecipitation, with the required reagents and the step-by-step procedure.
  • No Image
    Ten reasons to select Fortis Life Sciences for your bulk antibodies and reagents for your applications
    Assay development requires high-quality antibodies and reagents from suppliers that can deliver bulk quantities specific to your application and technical needs. Additionally, these projects require relationships with suppliers capable of providing long term support.
  • Exosomes - Lipid-based Extracellular Vesicles
    Exosomes are lipid-based extracellular vesicles. They are formed from the endosomal compartment, when endosomal vesicles fuse with the cell’s plasma membrane, releasing the endosome from the cell. Initial hypotheses about the function of exosomes were that they are part of the cellular recycling system, responsible for transporting waste out of the cell. They have also been described as playing an important role in cell-cell communication, where exosomes subsequently fuse with the plasma membrane of a target cell to transmit signals including proteins and RNA between cells1.
  • No Image
    White Paper: T-Cell Profiling
    T cells are the central regulators of the body’s immune system, and, when quantified, can provide significant insights about diseases. Immune profiling using high-quality, specific, and consistently performing antibodies is an important way to understand disease progression and predict response to treatments.
  • CD27: An Emerging Target for Cancer Immunotherapy
    Immune checkpoint molecules such as CTLA-4, PD-(L)1, and CD27, are a common target of immunotherapies against solid tumors. Targeting these molecules leads to the (re)activation of an immune response against a tumor, typically by blocking an inhibitory signal coming into the immune cell from either tumor cells or suppressive immune cells within the tumor microenvironment. The most well-known and earliest targets of checkpoint immunotherapies, targeting the PD-1/PD-L1 and CTLA-4 pathways, follow this mechanism and are known as checkpoint blockade immunotherapies. Immunotherapies that target CD27 function differently.
  • Targeting T regulatory cells in cancer immunotherapy with anti-CD73
    In the era of immunotherapy, a major focus of the field is to identify new targets that may improve the immune response to solid tumors. Recently, CD73 has been identified as a novel target for cancer immunotherapy. CD73, also known as ecto-5’-nucleotidase, is an enzyme that is involved in purinergic signaling1. CD73 is part of a conserved pathway in immune cells that begins with the activity of CD39 (also known as ENTPD1). Together, CD39 and CD73 are responsible for the breakdown of purines by immune cells. CD39 catalyzes the breakdown of ATP and ADP into AMP, and CD73 then converts AMP to adenosine. CD73 is the only known enzyme to have this function2. Both CD39 and CD73 are located at the cell surface and exert their enzymatic functions on extracellular adenosines3.